Nowa wersja platformy, zawierająca wyłącznie zasoby pełnotekstowe, jest już dostępna.
Przejdź na


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2008 | 3 | 2 | 167-172
Tytuł artykułu

Homocysteinemia, hypertension, and family history of diabetes in a smoking male population in Saudi Arabia

Treść / Zawartość
Warianty tytułu
Języki publikacji
Arabs have a lower incidence of atherosclerosis than other ethnicities, but few studies have examined homocysteine (HCYS) as a risk factor for cardiovascular disease in this population. Here, we investigated the association between serum HYCS levels and risk factors for cardiovascular disease (smoking, hypertension, and family history of diabetes) in Saudi males. A total of 50 smokers and 72 nonsmokers completed a general health questionnaire. In addition, their lipid profiles were measured using routine methods and HCYS levels by high-performance liquid chromatograph with electrochemical detection. Regression analysis showed negative associations between HCYS and glucose (r = −0.22; P < 0.05) as well as family history of diabetes (r = −0.21; P < 0.05). HCYS levels were similar between hypertensive and nonhypertensive smokers, but they were significantly elevated in hypertensive nonsmokers (P = 0.027) and lower in smokers with family history of diabetes (P = 0.01). Levels of HCYS among nonsmokers inversely correlated with history of diabetes and elevated glucose. Nonsmokers’ HCYS levels were significantly elevated in the presence of hypertension and correlated with diastolic blood pressure. Thus, HCYS may be a predictor of hypertension among nonsmokers. Until further trials are conducted, we recommend vitamin B6/folic acid supplementation for the Saudi hypertensive population as an adjuvant therapy.

Opis fizyczny
  • Biochemistry Department, King Saud University College of Science, P.O Box 2455, Riyadh, 11451, Kingdom of Saudi Arabia,
  • Biochemistry Department, King Saud University College of Science, P.O Box 2455, Riyadh, 11451, Kingdom of Saudi Arabia
  • [1] Bleie O., Semb A.G., Grundt H., Nordrehauq J.E., Vollset S.E., Ueland P.M., et al., Homocysteinelowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease, J. Intern. Med., 2007, 262, 244–253[Crossref]
  • [2] Wierzbicki A.S., Homocysteine and cardiovascular disease: a review of evidence, Diab. Vasc. Dis. Res., 2007, 4, 143–150[Crossref]
  • [3] Signorello M.G., Viviani G.L., Armani U., Cerone R., Minniti G., Piana A. et al., Homocysteine, reactive oxygen species and nitric oxide in type 2 diabetes mellitus, Thromb. Res., 2007, 120, 607–613[WoS][Crossref]
  • [4] Zakai N.A., Katz R., Jenny N.S., Psaty B.M., Reiner A.P., Schwartz S.M., et al., Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: the Cardiovascular Health Study, J. Thromb. Haemost., 2007, 5, 1125–1127[Crossref]
  • [5] Gonzales S., Huerta J.M., Fernandez S., Patterson A.M., Laceras C., Homocysteine increases the risk of mortality in elderly individuals, Br. J. Nutr., 2007, 97, 1128–1135[WoS][Crossref]
  • [6] Kennedy B.P., Faraq N.H., Ziegler M.G., Mills P.J., Relationship of systolic blood pressure with plasma homocysteine: importance of smoking status, J. Hypertens., 2003, 21, 1307–1312[Crossref]
  • [7] Pernod G., Bosson J.L., Golshayan D., Barro C., Alloatti S., Turc-Baron C., et al., Dialysis cohort study: clinico-biological characteristics and cardiovascular genetic risk profile of incident patients, J. Nephrol., 2004, 17, 66–75[Crossref]
  • [8] Retterstol L., Paus B., Bohn M., Bakken A., Erikssen J., Malinow M.R., Berq K., Plasma total homocysteine levels and prognosis in patients with previous premature myocardial infarction: a 10-year follow-up study, J. Intern. Med., 2003, 253, 284–292[Crossref]
  • [9] Castelli W.P., Epidemiology of coronary heart disease: the Framingham study, Am. J. Med., 1984, 76, 4–12[Crossref]
  • [10] Reis R.P., Azinheira J., Reis H.P., Pina J.E., Correia J.M., Luis A.S., Influence of smoking on homocysteinemia at baseline and alter methionine load, Rev. Port. Cardiol., 2000, 19, 471–474
  • [11] Sharper A.G., Pocock S.J., Walker M., Phillips A.N., Whitehead T.P., MacFarlane T.W., Risk factors for ischaemic heart disease: the prospective phase of the British Regional Heart Study, J. Epidemiol. Community Health, 1985, 39, 197–209[Crossref]
  • [12] Jarallah J.S., Al-Rubeaan K.A., Al-Nuaim A.R., Al-Ruhaily A.A., Kalantan K.A., Prevalence and determinants of smoking in three regions of Saudi Arabia, Tob. Control., 1999, 8, 53–56 [Crossref]
  • [13] Heidrich J., Wellman J., Heuschmann P.U., Kraywinkel K., Keil U., Mortality and morbidity from coronary heart disease attributable to smoking, Eur. Heart J., 2007, 20, 2498–502[Crossref]
  • [14] Leone A., Smoking, haemostatic factors and cardiovascular risk, Curr. Pharm. Des., 2007, 13, 1661–1667[Crossref]
  • [15] O’Callaghan P., Meleady R., Fitzgerald T., Graham I., European COMAC Group, Smoking and plasma homocysteine, Eur. Heart J., 2002, 23, 1580–1586[Crossref]
  • [16] Al-Nozha M.M., Arafah M.R., Al-Mazrou Y.Y., Al-Maatouq M.A., Khan N.B., Khalil M.Z., et. al., Coronary artery disease in Saudi Arabia. Saudi Med. J., 2004, 25, 1165–1171
  • [17] Pagan K., Hou J., Goldenberg R.L., Cliver S.P., Tamura T., Effect of smoking on serum concentrations of total homocysteine and B vitamins in mid-pregnancy, Clin. Chim. Acta., 2001, 306, 103–109[Crossref]
  • [18] Mc Carty M.F., Increased homocyst(e)ine associated with smoking, chronic inflammation, and aging may reflect acute phase induction of pyridoxal phosphatase activity, Med. Hypotheses, 2000, 55, 289–293[Crossref]
  • [19] Fanapour P.C., Yug B., Kocharn M.S., Hyperhomocysteinemia: an additional cardiovascular risk factor, W.M.J., 1999, 98, 51–54
  • [20] Giannetti N., Herity N.A., Alimollah A., Gao S.Z., Schroeder J.S., Yeung A.C., et al., Mild Hyperhomocysteinemia is not associated with cardiac allograft coronary disease, Clin. Transplant, 2001, 15, 247–252[Crossref]
  • [21] Lee B.J., Lin P.T., Liaw Y.P., Chang S.J., Cheng C.H., Huang Y.C., Homocysteine and risk of coronary artery disease: Folate is the important determinant of plasma homocysteine concentration, Nutrition, 2003, 19, 577–583[Crossref]
  • [22] Gazi I.F., Elisaf M., LDL-cholesterol calculation formulas in patients with or without metabolic syndrome, Int. J. Cardiol., 2007, 119, 414–415[Crossref][WoS]
  • [23] Martin S.C., Tsakas-Ampatzis I., Bartlett W.A., Jones A.F., Measurement of plasma homocysteine by HPLC with coulometric detection, Clin. Chem., 1999, 45, 150–152
  • [24] Lip G.Y., Edmunds E., Martin S.C., Jones A.F., Blann A.D., Beevers D.G., A pilot study of homocyst(e)ine levels in essential hypertension: relationship to von Willebrand factor, an index of endothelial damage, Am. J. Hypertens., 2001, 14, 627–631[Crossref]
  • [25] Tayama J., Munakata M., Yoshinaga K., Toyota T., Higher plasma homocysteine concentration is associated with more advanced systemic arterial stiffness and greater blood pressure response to stress in hypertensive patients, Hypertens. Res., 2006, 29, 403–409[Crossref]
  • [26] Boers G.H., Mild hyperhomocysteinemia is an independent risk factor of arterial vascular disease, Semin. Thromb. Hemost., 2000, 26, 291–295[Crossref]
  • [27] Rodrigo R., Passalacqua W., Arraya J., Orellana M., Rivera G., Homocysteine and essential hipertensión, J. Clin. Pharmacol., 2003, 43, 1299–1306[Crossref]
  • [28] Sundstrom J., Sullivan L., D’Agostino R.B., Jacques P.F., Selhub J., Rosenberg R.H. et. al., Plasma homocysteine, hypertension incidence, and blood pressure tracking: the Framingham Heart Study, Hypertension, 2003, 42, 1100–1105[Crossref]
  • [29] Stein J.H., Bushara M., Bushara K., McBride P.E., Jorenby D.E., Fiore M.C., Smoking cessation, but not smoking reduction, reduces plasma homocysteine levels, Clin. Cardiol., 2002, 25, 23–26[Crossref]
  • [30] Tonstad S., Urdal P., Does short-term smoking cessation reduce plasma total homocysteine concentrations? Scand. J. Clin. Lab. Invest, 2002, 62, 279–284[Crossref]
  • [31] Abu-Amero K.K., Wyngaard C.A., Dzimiri N., Prevalence and role of methylenetetrahydrofolate 677C-T and 1298A-C polymorphism in coronary artery disease in Arabs, Arch. Pathol. Lab. Med., 2003, 127, 1349–1352
  • [32] Bu R., Gutierrez M.I., Al-Rasheed M., Belgaumi A., Bhatia K., Variable drug metabolism genes in Arab population, Pharmacogenomics, 2004, 4, 260–266[Crossref]
  • [33] Blum A., Hijazi I., Eizenberg M.M., Blum N., Homocysteine (Hcy) follow-up, Clin. Invest Med., 2007, 30, 21–25
  • [34] Liao D., Tan H., Hui R., Li Z., Jiang X., Gaubatz J. et al., Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A1 protein synthesis and enhancing HDL cholesterol clearance, Circ. Res., 2006, 99, 565–566[Crossref]
  • [35] Al-Nozha M., Al-Daghri N., Bartlett W.A., Al-Attas O., Al-Maatouq M., Martin S.C., et al., Serum homocysteine concentration is related to diabetes mellitus, but not to coronary heart disease in Saudi Arabians, Diabetes Obes. Metab., 2002, 4, 118–123[Crossref]
Typ dokumentu
Identyfikator YADDA
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.